Imidazotriazolopyrimidines with adenosine-antagonistic activity

New imidazotriazolopyrimidine derivatives of the formulaPreferred are those compounds wherein:R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; orR1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopenty...

Full description

Saved in:
Bibliographic Details
Main Authors KUEFNER-MUEHL ULRIKE, MIERAU JOACHIM, BLECH STEFAN, HOFFMANN MATTHIAS, MEADE CHRISTOPHER JOHN MONTAGUE, POHL GERALD, WEISER THOMAS, LEHR ERICH, CARTER ADRIAN, KUMMER WERNER, GAIDA WOLFRAM
Format Patent
LanguageEnglish
Published 10.12.2002
Edition7
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:New imidazotriazolopyrimidine derivatives of the formulaPreferred are those compounds wherein:R1 denotes methyl, which is optionally substituted by phenyloxy or pyrrole; orR1 denotes benzyl which is optionally substituted by hydroxy, methoxy, dimethylaminoethoxy or fluorine; or R1 denotes cyclopentyl, furan or phenylethyl;R2 or R3 denote ethyl, n-propyl, allyl or propargyl;R4 or R6 denote hydrogen; and,R5 denotes methyl, n-propyl, tert.butyl, cyclopentyl or norbornenyl.These are adenosine antagonists are are useful for, inter alia, the treatment of senile dementia of the Alzheimer's type.
Bibliography:Application Number: US20000559806